The Biotech Investor: How to Profit from the Coming Boom in Biotechnology

Overview

The world is entering a biotechnology boom -- but only informed investors will prosper in the extremely complex biotech business. In The Biotech Investor, Tom Abate separates the bioengineered wheat from the chaff, offering the definitive guide to the science, finances, time horizon, and commercial potential of this burgeoning industry. Abate, a technology reporter for the San Francisco Chronicle, provides guidelines or assessing company leadership, easy-to-digest reports from ...
See more details below
Paperback (First Edition)
$14.94
BN.com price
(Save 21%)$19.00 List Price
Other sellers (Paperback)
  • All (14) from $1.99   
  • New (8) from $7.56   
  • Used (6) from $1.99   
The Biotech Investor: How to Profit from the Coming Boom in Biotechnology

Available on NOOK devices and apps  
  • NOOK Devices
  • Samsung Galaxy Tab 4 NOOK 7.0
  • Samsung Galaxy Tab 4 NOOK 10.1
  • NOOK HD Tablet
  • NOOK HD+ Tablet
  • NOOK eReaders
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook - First Edition)
$7.99
BN.com price

Overview

The world is entering a biotechnology boom -- but only informed investors will prosper in the extremely complex biotech business. In The Biotech Investor, Tom Abate separates the bioengineered wheat from the chaff, offering the definitive guide to the science, finances, time horizon, and commercial potential of this burgeoning industry. Abate, a technology reporter for the San Francisco Chronicle, provides guidelines or assessing company leadership, easy-to-digest reports from the labs, and indispens-able investor tools and metrics.

The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

Read More Show Less

Editorial Reviews

From the Publisher
“An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come.” —Brook H. Byers, partner, Kleiner Perkins Caufield & Byers
Publishers Weekly
With the population aging and eager for medical innovations, the market for biotechnology is vast. But for investors looking at biotech firms, it can be a minefield: before a company's brilliant ideas pan out as profitable products, they must go through years of costly research and development, clear government regulatory hurdles and sometimes, as with genetically modified foods, weather political controversy. This informative and well-written primer will help individual investors navigate the treacherous terrain of biotech stocks. Abate, a biotechnology and health care reporter for the San Francisco Chronicle, provides an overview of each sector of the biotechnology industry and the leading companies in it, tells where to find up-to-date information on the scientific and medical developments that drive the market, and explains how to evaluate the financial prospects of the often shaky start-ups that crowd the field. His advice is appropriately cautious; he suggests putting no more than 20% of a portfolio in biotechnology, and waiting until a company is in hailing distance of profitability before investing. While the book is pitched at the non-professional, Abate makes it clear that these speculative, volatile and often over-sold stocks demand more effort-he recommends reading scientific journals, attending conferences and perusing the patent literature -than a complacent mutual-fund investor is used to. But for those willing to brave the new world of biotechnology, this is a good place to start. 20 charts and graphs. (Feb.) Copyright 2003 Cahners Business Information.
Library Journal
Most investors are advised to buy and hold, but investing in biotechnology stock requires a different strategy. Because biotech medicines are experimental in nature and require strict regulatory review from the U.S. Food and Drug Administration, such investments usually are high risk, so why would anyone want to buy stocks in this sector? Abate, a biotechnology, technology, and healthcare reporter who writes a weekly "BioScope" column for the San Francisco Chronicle, here argues that the biotechnology sector has become especially interesting to investors owing to the maturation of biotech science and the aging of the population: "Companies in this industry are attacking the root causes of cancer, heart attack, Parkinson's disease and other modern scourges." Abate is forthright when discussing risk in this field and gives the reader the information needed to identify, evaluate, and invest in biotech companies. He discusses how to track stocks using the two biotech indexes on the stock exchange and indicates specific ways to search the Internet when investigating the biotechnology field. Like Jim McCamant's Biotech Investing: Every Investor's Guide, this book argues that now is the time to invest in biotech companies, but readers should remember that this is advisable only for high-risk investors. Such investors will find this book clear and understandable. Recommended for public libraries.-Bellinda Wise, Nassau Community Coll. Lib., Garden City, NY Copyright 2003 Reed Business Information.
Read More Show Less

Product Details

  • ISBN-13: 9780805075083
  • Publisher: Holt, Henry & Company, Inc.
  • Publication date: 12/28/2003
  • Edition description: First Edition
  • Pages: 308
  • Sales rank: 1,342,604
  • Product dimensions: 5.50 (w) x 8.50 (h) x 0.69 (d)

Meet the Author

Award-winning biotechnology, technology, and health care reporter Tom Abate writes the weekly BioScope column for the San Francisco Chronicle. He lives in San Leandro, California.

Read More Show Less

Table of Contents

Preface: The Biotech Wave
1 The Foundations of Biotech Investing 1
2 The Age Wave and the Market for New Medicines 23
3 The Genomics Wave: The Drug Discovery Marathon 47
4 The Proteomics Wave: Proteins and the Next Medicines 73
5 Picks and Shovels: The Biotech Toolmakers 97
6 Green Genes: Agricultural Biotechnology 121
7 The New Factories: Industrial Biotechnology 147
8 Brave New Worlds: Stem Cells, Clones, and Other Frontiers 169
9 The Biotech Clusters: Follow the Leaders 197
10 The Investment Frontier 219
App. I Public Biotechnology Firms 243
App. II Biotechnology Firms 261
App. III Research Resources 271
Acknowledgments 275
Index 279
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously
Sort by: Showing 1 Customer Reviews
  • Anonymous

    Posted May 26, 2007

    A reviewer

    First, this is an older book. The things spoken about in speak of things happening in 2001. The companies mentioned have since developed some the product already and have already gone on to become big. What you can look for is some of the companies that had things in the pipeline are now in Phase 2 and 3 stage right now. The book offers great advice and things to look out for. Websites things to read,trends to watch, and brief descriptions of various Biotech projects that are to come.

    Was this review helpful? Yes  No   Report this review
Sort by: Showing 1 Customer Reviews

If you find inappropriate content, please report it to Barnes & Noble
Why is this product inappropriate?
Comments (optional)